Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VH0X
|
|||
| Former ID |
DIB005771
|
|||
| Drug Name |
Tuberculosis vaccine
|
|||
| Synonyms |
RBCG30, UCLA; Tuberculosis vaccine, UCLA; Tuberculosis vaccine, University of California LosAngeles; RBCG30, UCLA/Aeras; Subunit TB vaccine, ID Vaccine/Aventis Pasteur; Subunit TB vaccine, ID Vaccine/PMC; TB subunit vaccine, ID Vaccine/Aventis Pasteur; TB subunit vaccine, ID Vaccine/PMC; Tuberculosis vaccine, ID Vaccine/Aventis Pasteur; Tuberculosis vaccine, ID Vaccine/PMC; Tuberculosis vaccine, UCLA/Aeras; Vaccine (TB), ID Vaccine/Aventis Pasteur; Vaccine (TB), ID Vaccine/Pasteur Merieux Connaught; Vaccine (tuberculosis), ID Vaccine/Aventis Pasteur; Vaccine (tuberculosis), ID Vaccine/PMC
Click to Show/Hide
|
|||
| Indication | Tuberculosis [ICD-11: 1B10-1B1Z; ICD-10: A15-A19, B90] | Phase 2 | [1] | |
| Mycobacterium infection [ICD-11: 1B10-1B21] | Phase 1 | [2] | ||
| Company |
University of California Los Angeles
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Aerus Global TB Vaccine Foundation. | |||
| REF 2 | New vaccine shows promise as stronger weapon against both tuberculosis and leprosy. Health + Behavior. Enrique Rivero, August 19, 2014. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.